Oppenheimer Upgrades Cubist Pharmaceuticals (CBST) to Perform
More News related to CBST
- After-Hours Movers 1/21: SOMX, CNXT, ISRG, NRG Higher; SYNA, IBKR, ACHN, COF, NAT, GOOG Lower
- Cubist Pharma (CBST) Posts Q4 adj.-EPS of $0.68, Tops Views
- Cubist Pharmaceuticals Announces Full Year 2009 Total Net Revenues of $562.1 Million
- Trading Radar for 1/21: Google (GOOG), Goldman Sachs (GS), Western Digital (WDC), Intuitive Surgical (ISRG) Report
- Cubist Pharma (CBST) Provides Q409 and FY09 Revenues
More News related to Upgrades
- Soleil Securities Upgrades Zebra Technologies (ZBRA) to Gradually Accumulate; Valuation Call
- UBS Issues Intraday Upgrade on Cimarex Energy (XEC)
- Boenning & Scattergood Upgrades Equinix (EQIX) to Outperform
- Avondale Partners Upgrades ADC Telecommunications (ADCT) to Market Outperform
- Johnson Rice Upgrades Pool Corp (POOL) to Overweight
Oppenheimer upgrades Cubist Pharmaceuticals (Nasdaq: CBST) from Underperform to Perform. Price target $17.
To see more analyst ratings on CBST Click Here.
Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.
Related Categories
UpgradesStocks Mentioned
+0.65Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
